Effects of Growth Hormone on Growth, Insulin Resistance and Related Hormones (Ghrelin, Leptin and Adiponectin) in Turner Syndrome
Background:Concomitant evaluation of the metabolic and growth-promoting effects of growth hormone (GH) therapy in Turner syndrome (TS) may be used in the prediction of the growth response to GH therapy. Aim: To evaluate the metabolic effects of GH therapy in TS and correlation with the short-term gr...
Gespeichert in:
Veröffentlicht in: | Hormone research 2007-01, Vol.68 (1), p.1-7 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 7 |
---|---|
container_issue | 1 |
container_start_page | 1 |
container_title | Hormone research |
container_volume | 68 |
creator | Darendeliler, Feyza Aycan, Zehra Cetinkaya, Ergun Vidilisan, Sadi Bas, Firdevs Bideci, Aysun Demirel, Fatma Darcan, Sukran Buyukgebiz, Atilla Yildiz, Metin Berberoglu, Merih Arslanoglu, Ilknur Bundak, Ruveyde |
description | Background:Concomitant evaluation of the metabolic and growth-promoting effects of growth hormone (GH) therapy in Turner syndrome (TS) may be used in the prediction of the growth response to GH therapy. Aim: To evaluate the metabolic effects of GH therapy in TS and correlation with the short-term growth response. Patients: 24 prepubertal children with TS, aged 9.4 ± 2.6 years were followed for auxology and IGF-I, IGFBP-3, leptin, ghrelin, adiponectin, lipids and OGTT results in a prospective multicenter study. Intervention: GH (Genotropin®) in a dose of 50 µg/kg/day for 1 year. Results: Height standard deviation score (SDS) increased from –3.9 ± 1.5 to –3.5 ± 1.4 (p = 0.000) on therapy. BMI did not change. IGF-I SDS increased from –2.3 ± 0.4 to –1.6 ± 1.1 at 3 and 6 months (p = 0.001) and decreased thereafter. Serum leptin decreased significantly from 2.3 ± 3.9 to 1.7 ± 5.3 ng/ml (p = 0.022) at 3 months and increased afterwards. Serum ghrelin decreased from 1.2 ± 0.8 to 0.9 ± 0.4 ng/ml (p = 0.005) with no change in adiponectin. Basal and stimulated insulin levels also increased significantly. Δ height SDS over 1 year showed a significant correlation with Δ IGF-I 0–3 months (r = 0.450, p = 0.027). Conclusion: IGF-I may be considered as a marker of growth response in TS at short term. Leptin shows a decrease at short term but does not have a correlation with growth response. The decrease in ghrelin in face of unchanged weight seems to be associated with increase in IGF-I and insulin levels. The unchanged adiponectin levels in spite of an increase in insulin levels indicates that adiponectin is mainly affected by weight, not insulin. |
doi_str_mv | 10.1159/000098440 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1159_000098440</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2837639511</sourcerecordid><originalsourceid>FETCH-LOGICAL-c261t-a9fb251b184d324a7ac78cf2341e1debbca2cdf372bb560fe15e8da16d9a96133</originalsourceid><addsrcrecordid>eNpd0VFLHDEQAOAglSrqQ5-FEiiIgmczyW42-yiip3AgqH1essmkrt1Nrskuxcf-c3PceYIhkEzyzTAwhHwDdgFQ1j9ZXrUqCrZD9kFKMeOKyy_bO6g9cpTSy4oJVdVQfSV7UHFWKFHtk__XzqEZEw2OzmP4Nz7T2xCH4JEGv3k5p3c-TX3n6QOmLo3aG6Ta2xz2ekT7npHo6fw5YobndIHLMSes1KXtlvnX5PiM5renKXqM9PHV2xgGPCS7TvcJjzbnAfl1c_10dTtb3M_vri4XM8MljDNdu5aX0IIqrOCFrrSplHFcFIBgsW2N5sY6UfG2LSVzCCUqq0HaWtcShDggJ-u6yxj-TpjGZuiSwb7XHsOUmopJJnlRZvjjE3wJueXcWwNciLwFU1mdrZWJIaWIrlnGbtDxtQHWrAbTbAeT7fdNxakd0H7IzRgyOF6DPzr-xrgF6_Q363uQ2w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1233233308</pqid></control><display><type>article</type><title>Effects of Growth Hormone on Growth, Insulin Resistance and Related Hormones (Ghrelin, Leptin and Adiponectin) in Turner Syndrome</title><source>Karger e-journals Complete Collection</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Darendeliler, Feyza ; Aycan, Zehra ; Cetinkaya, Ergun ; Vidilisan, Sadi ; Bas, Firdevs ; Bideci, Aysun ; Demirel, Fatma ; Darcan, Sukran ; Buyukgebiz, Atilla ; Yildiz, Metin ; Berberoglu, Merih ; Arslanoglu, Ilknur ; Bundak, Ruveyde</creator><creatorcontrib>Darendeliler, Feyza ; Aycan, Zehra ; Cetinkaya, Ergun ; Vidilisan, Sadi ; Bas, Firdevs ; Bideci, Aysun ; Demirel, Fatma ; Darcan, Sukran ; Buyukgebiz, Atilla ; Yildiz, Metin ; Berberoglu, Merih ; Arslanoglu, Ilknur ; Bundak, Ruveyde</creatorcontrib><description>Background:Concomitant evaluation of the metabolic and growth-promoting effects of growth hormone (GH) therapy in Turner syndrome (TS) may be used in the prediction of the growth response to GH therapy. Aim: To evaluate the metabolic effects of GH therapy in TS and correlation with the short-term growth response. Patients: 24 prepubertal children with TS, aged 9.4 ± 2.6 years were followed for auxology and IGF-I, IGFBP-3, leptin, ghrelin, adiponectin, lipids and OGTT results in a prospective multicenter study. Intervention: GH (Genotropin®) in a dose of 50 µg/kg/day for 1 year. Results: Height standard deviation score (SDS) increased from –3.9 ± 1.5 to –3.5 ± 1.4 (p = 0.000) on therapy. BMI did not change. IGF-I SDS increased from –2.3 ± 0.4 to –1.6 ± 1.1 at 3 and 6 months (p = 0.001) and decreased thereafter. Serum leptin decreased significantly from 2.3 ± 3.9 to 1.7 ± 5.3 ng/ml (p = 0.022) at 3 months and increased afterwards. Serum ghrelin decreased from 1.2 ± 0.8 to 0.9 ± 0.4 ng/ml (p = 0.005) with no change in adiponectin. Basal and stimulated insulin levels also increased significantly. Δ height SDS over 1 year showed a significant correlation with Δ IGF-I 0–3 months (r = 0.450, p = 0.027). Conclusion: IGF-I may be considered as a marker of growth response in TS at short term. Leptin shows a decrease at short term but does not have a correlation with growth response. The decrease in ghrelin in face of unchanged weight seems to be associated with increase in IGF-I and insulin levels. The unchanged adiponectin levels in spite of an increase in insulin levels indicates that adiponectin is mainly affected by weight, not insulin.</description><identifier>ISSN: 1663-2818</identifier><identifier>EISSN: 1663-2826</identifier><identifier>EISSN: 1423-0046</identifier><identifier>DOI: 10.1159/000098440</identifier><identifier>PMID: 17204837</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adiponectin - blood ; Child ; Child, Preschool ; Cholesterol - blood ; Female ; Ghrelin ; Growth - drug effects ; Human Growth Hormone - pharmacology ; Human Growth Hormone - therapeutic use ; Humans ; Insulin Resistance ; Leptin - blood ; Original Paper ; Peptide Hormones - blood ; Peptide Hormones - drug effects ; Triglycerides - blood ; Turner Syndrome - blood ; Turner Syndrome - drug therapy ; Turner Syndrome - physiopathology</subject><ispartof>Hormone research, 2007-01, Vol.68 (1), p.1-7</ispartof><rights>2007 S. Karger AG, Basel</rights><rights>Copyright 2007 S. Karger AG, Basel.</rights><rights>Copyright (c) 2007 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c261t-a9fb251b184d324a7ac78cf2341e1debbca2cdf372bb560fe15e8da16d9a96133</citedby><cites>FETCH-LOGICAL-c261t-a9fb251b184d324a7ac78cf2341e1debbca2cdf372bb560fe15e8da16d9a96133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,2430,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17204837$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Darendeliler, Feyza</creatorcontrib><creatorcontrib>Aycan, Zehra</creatorcontrib><creatorcontrib>Cetinkaya, Ergun</creatorcontrib><creatorcontrib>Vidilisan, Sadi</creatorcontrib><creatorcontrib>Bas, Firdevs</creatorcontrib><creatorcontrib>Bideci, Aysun</creatorcontrib><creatorcontrib>Demirel, Fatma</creatorcontrib><creatorcontrib>Darcan, Sukran</creatorcontrib><creatorcontrib>Buyukgebiz, Atilla</creatorcontrib><creatorcontrib>Yildiz, Metin</creatorcontrib><creatorcontrib>Berberoglu, Merih</creatorcontrib><creatorcontrib>Arslanoglu, Ilknur</creatorcontrib><creatorcontrib>Bundak, Ruveyde</creatorcontrib><title>Effects of Growth Hormone on Growth, Insulin Resistance and Related Hormones (Ghrelin, Leptin and Adiponectin) in Turner Syndrome</title><title>Hormone research</title><addtitle>Horm Res Paediatr</addtitle><description>Background:Concomitant evaluation of the metabolic and growth-promoting effects of growth hormone (GH) therapy in Turner syndrome (TS) may be used in the prediction of the growth response to GH therapy. Aim: To evaluate the metabolic effects of GH therapy in TS and correlation with the short-term growth response. Patients: 24 prepubertal children with TS, aged 9.4 ± 2.6 years were followed for auxology and IGF-I, IGFBP-3, leptin, ghrelin, adiponectin, lipids and OGTT results in a prospective multicenter study. Intervention: GH (Genotropin®) in a dose of 50 µg/kg/day for 1 year. Results: Height standard deviation score (SDS) increased from –3.9 ± 1.5 to –3.5 ± 1.4 (p = 0.000) on therapy. BMI did not change. IGF-I SDS increased from –2.3 ± 0.4 to –1.6 ± 1.1 at 3 and 6 months (p = 0.001) and decreased thereafter. Serum leptin decreased significantly from 2.3 ± 3.9 to 1.7 ± 5.3 ng/ml (p = 0.022) at 3 months and increased afterwards. Serum ghrelin decreased from 1.2 ± 0.8 to 0.9 ± 0.4 ng/ml (p = 0.005) with no change in adiponectin. Basal and stimulated insulin levels also increased significantly. Δ height SDS over 1 year showed a significant correlation with Δ IGF-I 0–3 months (r = 0.450, p = 0.027). Conclusion: IGF-I may be considered as a marker of growth response in TS at short term. Leptin shows a decrease at short term but does not have a correlation with growth response. The decrease in ghrelin in face of unchanged weight seems to be associated with increase in IGF-I and insulin levels. The unchanged adiponectin levels in spite of an increase in insulin levels indicates that adiponectin is mainly affected by weight, not insulin.</description><subject>Adiponectin - blood</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cholesterol - blood</subject><subject>Female</subject><subject>Ghrelin</subject><subject>Growth - drug effects</subject><subject>Human Growth Hormone - pharmacology</subject><subject>Human Growth Hormone - therapeutic use</subject><subject>Humans</subject><subject>Insulin Resistance</subject><subject>Leptin - blood</subject><subject>Original Paper</subject><subject>Peptide Hormones - blood</subject><subject>Peptide Hormones - drug effects</subject><subject>Triglycerides - blood</subject><subject>Turner Syndrome - blood</subject><subject>Turner Syndrome - drug therapy</subject><subject>Turner Syndrome - physiopathology</subject><issn>1663-2818</issn><issn>1663-2826</issn><issn>1423-0046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0VFLHDEQAOAglSrqQ5-FEiiIgmczyW42-yiip3AgqH1essmkrt1Nrskuxcf-c3PceYIhkEzyzTAwhHwDdgFQ1j9ZXrUqCrZD9kFKMeOKyy_bO6g9cpTSy4oJVdVQfSV7UHFWKFHtk__XzqEZEw2OzmP4Nz7T2xCH4JEGv3k5p3c-TX3n6QOmLo3aG6Ta2xz2ekT7npHo6fw5YobndIHLMSes1KXtlvnX5PiM5renKXqM9PHV2xgGPCS7TvcJjzbnAfl1c_10dTtb3M_vri4XM8MljDNdu5aX0IIqrOCFrrSplHFcFIBgsW2N5sY6UfG2LSVzCCUqq0HaWtcShDggJ-u6yxj-TpjGZuiSwb7XHsOUmopJJnlRZvjjE3wJueXcWwNciLwFU1mdrZWJIaWIrlnGbtDxtQHWrAbTbAeT7fdNxakd0H7IzRgyOF6DPzr-xrgF6_Q363uQ2w</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Darendeliler, Feyza</creator><creator>Aycan, Zehra</creator><creator>Cetinkaya, Ergun</creator><creator>Vidilisan, Sadi</creator><creator>Bas, Firdevs</creator><creator>Bideci, Aysun</creator><creator>Demirel, Fatma</creator><creator>Darcan, Sukran</creator><creator>Buyukgebiz, Atilla</creator><creator>Yildiz, Metin</creator><creator>Berberoglu, Merih</creator><creator>Arslanoglu, Ilknur</creator><creator>Bundak, Ruveyde</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Effects of Growth Hormone on Growth, Insulin Resistance and Related Hormones (Ghrelin, Leptin and Adiponectin) in Turner Syndrome</title><author>Darendeliler, Feyza ; Aycan, Zehra ; Cetinkaya, Ergun ; Vidilisan, Sadi ; Bas, Firdevs ; Bideci, Aysun ; Demirel, Fatma ; Darcan, Sukran ; Buyukgebiz, Atilla ; Yildiz, Metin ; Berberoglu, Merih ; Arslanoglu, Ilknur ; Bundak, Ruveyde</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c261t-a9fb251b184d324a7ac78cf2341e1debbca2cdf372bb560fe15e8da16d9a96133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adiponectin - blood</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cholesterol - blood</topic><topic>Female</topic><topic>Ghrelin</topic><topic>Growth - drug effects</topic><topic>Human Growth Hormone - pharmacology</topic><topic>Human Growth Hormone - therapeutic use</topic><topic>Humans</topic><topic>Insulin Resistance</topic><topic>Leptin - blood</topic><topic>Original Paper</topic><topic>Peptide Hormones - blood</topic><topic>Peptide Hormones - drug effects</topic><topic>Triglycerides - blood</topic><topic>Turner Syndrome - blood</topic><topic>Turner Syndrome - drug therapy</topic><topic>Turner Syndrome - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Darendeliler, Feyza</creatorcontrib><creatorcontrib>Aycan, Zehra</creatorcontrib><creatorcontrib>Cetinkaya, Ergun</creatorcontrib><creatorcontrib>Vidilisan, Sadi</creatorcontrib><creatorcontrib>Bas, Firdevs</creatorcontrib><creatorcontrib>Bideci, Aysun</creatorcontrib><creatorcontrib>Demirel, Fatma</creatorcontrib><creatorcontrib>Darcan, Sukran</creatorcontrib><creatorcontrib>Buyukgebiz, Atilla</creatorcontrib><creatorcontrib>Yildiz, Metin</creatorcontrib><creatorcontrib>Berberoglu, Merih</creatorcontrib><creatorcontrib>Arslanoglu, Ilknur</creatorcontrib><creatorcontrib>Bundak, Ruveyde</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hormone research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Darendeliler, Feyza</au><au>Aycan, Zehra</au><au>Cetinkaya, Ergun</au><au>Vidilisan, Sadi</au><au>Bas, Firdevs</au><au>Bideci, Aysun</au><au>Demirel, Fatma</au><au>Darcan, Sukran</au><au>Buyukgebiz, Atilla</au><au>Yildiz, Metin</au><au>Berberoglu, Merih</au><au>Arslanoglu, Ilknur</au><au>Bundak, Ruveyde</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Growth Hormone on Growth, Insulin Resistance and Related Hormones (Ghrelin, Leptin and Adiponectin) in Turner Syndrome</atitle><jtitle>Hormone research</jtitle><addtitle>Horm Res Paediatr</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>68</volume><issue>1</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>1663-2818</issn><eissn>1663-2826</eissn><eissn>1423-0046</eissn><abstract>Background:Concomitant evaluation of the metabolic and growth-promoting effects of growth hormone (GH) therapy in Turner syndrome (TS) may be used in the prediction of the growth response to GH therapy. Aim: To evaluate the metabolic effects of GH therapy in TS and correlation with the short-term growth response. Patients: 24 prepubertal children with TS, aged 9.4 ± 2.6 years were followed for auxology and IGF-I, IGFBP-3, leptin, ghrelin, adiponectin, lipids and OGTT results in a prospective multicenter study. Intervention: GH (Genotropin®) in a dose of 50 µg/kg/day for 1 year. Results: Height standard deviation score (SDS) increased from –3.9 ± 1.5 to –3.5 ± 1.4 (p = 0.000) on therapy. BMI did not change. IGF-I SDS increased from –2.3 ± 0.4 to –1.6 ± 1.1 at 3 and 6 months (p = 0.001) and decreased thereafter. Serum leptin decreased significantly from 2.3 ± 3.9 to 1.7 ± 5.3 ng/ml (p = 0.022) at 3 months and increased afterwards. Serum ghrelin decreased from 1.2 ± 0.8 to 0.9 ± 0.4 ng/ml (p = 0.005) with no change in adiponectin. Basal and stimulated insulin levels also increased significantly. Δ height SDS over 1 year showed a significant correlation with Δ IGF-I 0–3 months (r = 0.450, p = 0.027). Conclusion: IGF-I may be considered as a marker of growth response in TS at short term. Leptin shows a decrease at short term but does not have a correlation with growth response. The decrease in ghrelin in face of unchanged weight seems to be associated with increase in IGF-I and insulin levels. The unchanged adiponectin levels in spite of an increase in insulin levels indicates that adiponectin is mainly affected by weight, not insulin.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>17204837</pmid><doi>10.1159/000098440</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1663-2818 |
ispartof | Hormone research, 2007-01, Vol.68 (1), p.1-7 |
issn | 1663-2818 1663-2826 1423-0046 |
language | eng |
recordid | cdi_crossref_primary_10_1159_000098440 |
source | Karger e-journals Complete Collection; MEDLINE; Alma/SFX Local Collection |
subjects | Adiponectin - blood Child Child, Preschool Cholesterol - blood Female Ghrelin Growth - drug effects Human Growth Hormone - pharmacology Human Growth Hormone - therapeutic use Humans Insulin Resistance Leptin - blood Original Paper Peptide Hormones - blood Peptide Hormones - drug effects Triglycerides - blood Turner Syndrome - blood Turner Syndrome - drug therapy Turner Syndrome - physiopathology |
title | Effects of Growth Hormone on Growth, Insulin Resistance and Related Hormones (Ghrelin, Leptin and Adiponectin) in Turner Syndrome |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T20%3A51%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Growth%20Hormone%20on%20Growth,%20Insulin%20Resistance%20and%20Related%20Hormones%20(Ghrelin,%20Leptin%20and%20Adiponectin)%20in%20Turner%20Syndrome&rft.jtitle=Hormone%20research&rft.au=Darendeliler,%20Feyza&rft.date=2007-01-01&rft.volume=68&rft.issue=1&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=1663-2818&rft.eissn=1663-2826&rft_id=info:doi/10.1159/000098440&rft_dat=%3Cproquest_cross%3E2837639511%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1233233308&rft_id=info:pmid/17204837&rfr_iscdi=true |